kemalbas/iStock via Getty ImagesMRK stock: Still a Buy We last covered Merck (NYSE:MRK) back in July 2022 with a bullish thesis (as you can see from the chart below). At that time, the stock was trading around $75 per share at about 12.5x FWD P/E. And the bullish thesis was pretty obvious to us (with our key points quoted below). Merck, currently priced at about 12.5x FW P/E, is still undervalued by a sizable margin. Growth from pipeline drugs and especially Molnupiravir is not properly priced in, leadi ...

Merck (MRK) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that the company is excessively dependent on the drug and should look for ways to dive ...

Merck (MRK) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRK broke through the 20-day moving average, which suggests a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term m ...

Merck & Co., Inc. (NYSE:MRK) BofA Securities 2024 Health Care Conference May 15, 2024 4:40 PM ET Company Participants Caroline Litchfield - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Securities Geoff Meacham [Call Starts abruptly] Caroline Litchfield, CFO. Caroline, good to see you. Caroline Litchfield Great to see you again too. Geoff Meacham Thanks for joining. I know we have a list of questions, but maybe just kind of give us the post 1Q highlights and kind of how you see mayb ...

Merck & Co., Inc. (NYSE:MRK) BofA Securities 2024 Health Care Conference May 15, 2024 4:40 PM ET Company Participants Caroline Litchfield - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Securities Geoff Meacham [Call Starts abruptly] Caroline Litchfield, CFO. Caroline, good to see you. Caroline Litchfield Great to see you again too. Geoff Meacham Thanks for joining. I know we have a list of questions, but maybe just kind of give us the post 1Q highlights and kind of how you see mayb ...

Merck (MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma.Data from a pre-planned analysis of the study called KeyVibe-010 showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of patients discontinued all adjuvant therapy ...

A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors. A good example is the flow of funds into undervalued healthcare stocks during the pandemic. It didn’t take long for healthcare stocks to trade at premium valuations. Similarly, e-commerce and online education stocks surged during the pandemic.Once the concerns related to the pandemic eased, funds flowed to sectors negatively impacted by social di ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this pharmaceutical company have returned +2.2% over the past month versus the Zacks S&P 500 composite's -0.3% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck belongs, has gained 1.1% over this period. Now the key question is: Where could the stock be headed in the near term?Although media ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 22-1918501 (State or other jurisdiction o ...

Merck & Co., Inc. (NYSE:MRK) Q1 2024 Results Conference Call April 25, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Dana Graybosch - Leerink Partners James Shin - Deutsche Bank Umer Raffat - Evercore Tim Anderson - Wolfe Research Louise Chen - Cantor Fitzgerald Trun ...